Enovis Q2 2026: Sales Beat, Adjusted EPS Tops Estimates, Full-Year Guidance Reaffirmed
ENOV sits 58% above its 52-week low of $19.14.
Summary
Enovis posted Q2 2026 sales of $582.8M and adjusted EPS of $0.90, beating estimates, and reaffirmed full-year guidance. Both segments grew organically, margins expanded, and operating income turned positive.
Key Events · Earnings and Guidance · ENOV
-
Q2 Sales and EPS Beat
Net sales of $582.8M slightly exceeded the $582.5M consensus, while adjusted EPS of $0.90 beat the $0.85 estimate by $0.05.
-
Full-Year Guidance Reaffirmed
Management reaffirmed its full-year 2026 outlook, indicating confidence in continued growth across both segments.
-
Organic Growth Across Segments
Reconstructive segment organic sales grew 6.3%, and Prevention & Recovery grew 3.5%, driven by volume and higher-margin product mix.
-
Margin Expansion
Gross margin improved 230 bps to 61.6%, helped by a $6M reduction in inventory step-up amortization and a $4M net tariff benefit.
Analysis · ENOV · Industrial Applications And Services
Enovis delivered a solid quarter with sales of $582.8 million, edging past consensus, and adjusted EPS of $0.90, beating estimates by $0.05. Both segments grew organically, with Reconstructive leading at 6.3% organic growth. Gross margin expanded 230 basis points, driven by lower inventory step-up charges and a net tariff benefit. The company reaffirmed its full-year outlook, signaling confidence in sustained momentum. Operating income swung to a $17.4 million profit from a loss last year, and adjusted EBITDA rose 14% to $104.3 million. Cash reserves tightened to $12.6 million, but $942 million remains available on the revolver, providing ample liquidity.
At the time of this filing, ENOV was trading at $30.18 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $19.14 to $34.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.